Recent evidence supports benefits of glucagon-like peptide-1 (GLP-1) agonists exendin-4 (Exe) and liraglutide (LIRA) against diabetic cardiomyopathy. The gene discussed is GLP1R; the disease is diabetic cardiomyopathy.